Clinical Trial Update: A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating MK-1045 (CN201) for safety and early activity in relapsed or refractory B-cell non-Hodgkin lymphoma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory B-cell Non-hodgkin Lymphoma

Drugs mentioned

• MK-1045 (CN201)

Snippet

Sponsor: MSD R&D (China) Co., Ltd. | Conditions: Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING